Search Results - "Moatamed, Neda"

Refine Results
  1. 1

    Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas by Kassardjian, Ari, Shintaku, Peter I, Moatamed, Neda A

    Published in PloS one (19-04-2018)
    “…Immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and the programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) have…”
    Get full text
    Journal Article
  2. 2

    Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers by Singh, Tanya, Neal, Adam, Dibernardo, Gabriella, Raheseparian, Neela, Moatamed, Neda A, Memarzadeh, Sanaz

    Published in International journal of oncology (01-03-2022)
    “…Patients diagnosed with epithelial ovarian cancers (EOCs) often suffer from disease relapse associated with the emergence of resistance to standard…”
    Get full text
    Journal Article
  3. 3

    Functional expression of sodium-glucose transporters in cancer by Scafoglio, Claudio, Bruce A. Hirayama, Vladimir Kepe, Jie Liu, Chiara Ghezzi, Nagichettiar Satyamurthy, Neda A. Moatamed, Jiaoti Huang, Hermann Koepsell, Jorge R. Barrio, Ernest M. Wright

    “…Glucose is a major metabolic substrate required for cancer cell survival and growth. It is mainly imported into cells by facilitated glucose transporters…”
    Get full text
    Journal Article
  4. 4

    Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers by Moatamed, Neda A, Vahdatshariatpanahi, Saba, Gjertson, David W, Sachs, Chana R, Kang, Yuna, Ostrzega, Nora, Huang, Jiaoti, Memarzadeh, Sanaz

    Published in PloS one (19-09-2023)
    “…Introduction The expression of androgen receptor (AR) is not commonly tested or studied in uterine cancers, unlike estrogen receptor (ER) and progesterone…”
    Get full text
    Journal Article
  5. 5

    Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas by Reddy, Opal L, Shintaku, Peter I, Moatamed, Neda A

    Published in Diagnostic pathology (17-06-2017)
    “…The programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) immune regulatory axis has emerged as a promising new target for cancer therapeutics, with…”
    Get full text
    Journal Article
  6. 6

    A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids by Phan, Nhan, Hong, Jenny J., Tofig, Bobby, Mapua, Matthew, Elashoff, David, Moatamed, Neda A., Huang, Jin, Memarzadeh, Sanaz, Damoiseaux, Robert, Soragni, Alice

    Published in Communications biology (25-02-2019)
    “…Tumor organoids maintain cell–cell interactions, heterogeneity, microenvironment, and drug response of the sample they originate from. Thus, there is…”
    Get full text
    Journal Article
  7. 7

    Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer by Singh, Tanya, Neal, Adam S, Moatamed, Neda A, Memarzadeh, Sanaz

    “…One of the major challenges in the treatment of cancer are differential responses of patients to existing standard of care anti-cancer drugs. These…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression by Nilforoushan, Neshat, Moatamed, Neda A.

    Published in Annals of diagnostic pathology (01-10-2020)
    “…Serous borderline tumors (SBT) are the most common subtype of ovarian borderline tumors with excellent clinical course. However, they can recur or progress to…”
    Get full text
    Journal Article
  10. 10

    THADA‐IGF2BP3 gene fusions in thyroid fine needle aspiration is involved in the pathway to “noninvasive follicular thyroid neoplasm with papillary‐like nuclear features” by Zand, Amanda, Kim, Teresa H., Rodriguez, Erika F., Moatamed, Neda A.

    Published in Diagnostic cytopathology (01-11-2024)
    “…Background The increased usage and adaptation of molecular testing of thyroid fine needle aspirations (FNA) has expanded the variety and number of gene fusions…”
    Get full text
    Journal Article
  11. 11

    The uterine pathological features associated with sentinel lymph node metastasis in endometrial carcinomas by Kang, Yuna, Kim, Teresa H, Gjertson, David W, Cohen, Joshua G, Memarzadeh, Sanaz, Moatamed, Neda A

    Published in PloS one (24-11-2020)
    “…In recent years, sentinel lymph node excision and ultrastaging have been performed in endometrial carcinomas to obtain information about lymph node status,…”
    Get full text
    Journal Article
  12. 12

    Accuracy of frozen section remote subspecialty consultation using real-time telepathology and whole-slide imaging in gynecologic cases by Treece, Charisse Liz B, Filipek, Jennifer, Makker, Jitin, Moatamed, Neda A, Rodriguez, Erika F

    Published in American journal of clinical pathology (04-01-2024)
    “…Abstract Objectives Intrapathology consultation is recommended for complex cases during frozen section (FS) as routine practice. In our institution, solicited…”
    Get full text
    Journal Article
  13. 13

    Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4), and CD137 in cervical carcinoma by Kassardjian, Ari, Moatamed, Neda A

    “…Immune checkpoint inhibitors have a significant role in oncology. One of these immune checkpoints is cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)…”
    Get full text
    Journal Article
  14. 14

    "Copy number alteration" as the sole molecular finding of a Thyroseq test is more commonly seen in Hurthle cell neoplasms by Kim, Teresa H, Rodriguez, Erika F, Lim, Douglas, Moatamed, Neda A

    Published in Diagnostic cytopathology (01-11-2023)
    “…To better understand the molecular alterations associated with Hurthle cell lesions of the thyroid, we retrospectively reviewed the association of clonal DNA…”
    Get full text
    Journal Article
  15. 15
  16. 16

    ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas by Mah, Vei, Elshimali, Yahya, Chu, Alison, Moatamed, Neda A., Uzzell, Jamar P., Tsui, Jessica, Schettler, Stephen, Shakeri, Hania, Wadehra, Madhuri

    Published in Scientific reports (07-06-2021)
    “…In type 1 endometrial cancer, unopposed estrogen stimulation is thought to lead to endometrial hyperplasia which precedes malignant progression. Recent data…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Tumor necrosis factor receptor signaling modulates carcinogenesis in a mouse model of breast cancer by He, Ling, Bhat, Kruttika, Duhacheck-Muggy, Sara, Ioannidis, Angeliki, Zhang, Le, Nguyen, Nhan T., Moatamed, Neda A., Pajonk, Frank

    Published in Neoplasia (New York, N.Y.) (01-02-2021)
    “…Pro-inflammatory conditions have long been associated with mammary carcinogenesis and breast cancer progression. The underlying mechanisms are incompletely…”
    Get full text
    Journal Article
  19. 19

    p16 is superior to Stathmin-1 and HSP27 in identifying cervical dysplasia by Liou, Sofia, Nilforoushan, Neshat, Kang, Yuna, Moatamed, Neda A

    Published in Diagnostic pathology (20-09-2021)
    “…The aim of this study was to determine how Stathmin-1 and Heat Shock Protein 27 (HSP27) can be used as adjunctive biomarkers to differentiate high-grade…”
    Get full text
    Journal Article
  20. 20

    Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single‐institutional experience by Geng, Yipeng, Aguilar‐Jakthong, Josephine S., Moatamed, Neda A.

    Published in Cytopathology (Oxford) (01-03-2021)
    “…Introduction The Afirma test has been used in the diagnosis of cytologically indeterminate thyroid nodules to reduce diagnostic uncertainty and unnecessary…”
    Get full text
    Journal Article